



THE BRITISH JOURNAL OF PSYCHIATRY

FEBRUARY 1997 VOL. 170

EDITORIALS

101 National Confidential Inquiry into Suicide and Homicide by People with Mental Illness

L. Appleby, J. Shaw and T. Amos

103 Prion diseases

S. Fleminger and D. Curtis

REVIEW ARTICLE

106 Hyperekplexia: abnormal startle response due to glycine receptor mutations

M. Andrew and M. J. Owen

PAPERS

109 Impact factors of psychiatric journals

L. Howard and G. Wilkinson

113 A randomised controlled trial and cost analysis of problem-solving treatment for emotional disorders given by community nurses in primary care

L. Mynors-Wallis, I. Davies, A. Gray, F. Barbour and D. Gath

120 Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity

M. Hotopf, R. Hardy and G. Lewis

128 Prenatal and neonatal risk factors for schizophrenia

C. M. Hultman, A. Öhman, S. Cnattingius, I.-M. Wieselgren and L. H. Lindström

134 Neuropsychological correlates of syndromes in schizophrenia

R. M. G. Norman, A. K. Malla, S. L. Morrison-Stewart, E. Helmes, P. C. Williamson, J. Thomas and L. Cortese

140 Phenomenological differences appearing with repetitive behaviours in obsessive-compulsive disorder and Gilles de la Tourette's syndrome

E. C. Miguel, L. Baer, B. J. Coffey, S. L. Rauch, C. R. Savage, R. L. O'Sullivan, K. Phillips, C. Moretti, J. F. Leckman and M. A. Jenike

146 Huntington's disease: psychiatric practice in molecular genetic prediction and diagnosis

J. Scahill, D. Scahill, L. Gras, C. Hourigan and P. S. Harper

150 Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia

B. L. Miller, A. Darby, D. F. Benson, J. L. Cummings and M. H. Miller

156 Neuropsychological performance in Lewy body dementia and Alzheimer's disease

Z. Walker, R. L. Allen, S. Shergill and C. L. E. Katona

159 Enhanced growth hormone responses to pyridostigmine challenge in patients with panic disorder

J. M. Cooney, J. V. Lucey and T. G. Dinan

162 Genetic anticipation and imprinting in bipolar I illness

M. Grigoriou-Serbanescu, P. J. Wickramaratne, S. E. Hodge, S. Milea and R. Mihailescu

167 Subjective ratings of emotional health as a risk factor for major depression in a community sample

R. A. Hoff, M. L. Bruce, S. V. Kasl and S. C. Jacobs

173 Perceived parental styles in a Japanese sample of depressive disorders. A replication outside Western culture

T. Sato, K. Sakado, T. Uehara, K. Nishioka and Y. Kasahara

176 Patterns of hypnotic drug prescription in Italy. A two-week community survey

M. Balestrieri, M. Bortolomasi, M. Galletta and C. Bellantuono

181 HIV infection in psychiatric patients: an unlinked anonymous study

J. L. Ayuso-Mateos, F. Montañés, I. Lastra, J. J. Picazo de la Garza and J. L. Ayuso-Gutiérrez

186 Total mortality in people admitted to a psychiatric hospital

V. Hansen, E. Arnesen and B. K. Jacobsen

COLUMNS

191 Correspondence

194 One hundred years ago

195 Book reviews

197 Contents of *The American Journal of Psychiatry*

MAR 31 1997

LIBRARY OF
HARVARD HOSPITAL
37 AVENUE
CAMBRIDGE, MASS. 02138

George doesn't know what **SSRI** means ...

... He just knows his doctor
made a logical choice



“... **SSRIs** deserve consideration
as first-line therapy for
depression in older patients”



Cipramil▼
citalopram
your partner in depression

Presentation: 'Cipramil' tablets. PL 0458/0058, each containing 20mg of citalopram as the hydrobromide. 28 (OP) 20mg tablets £21.28. **Indications:** Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence. **Dosage: Adults:** 20mg a day. Depending upon individual patient response, this may be increased in 20mg increments to a maximum of 60mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. **Elderly:** 20mg a day increasing to a maximum of 40mg dependent upon individual patient response. **Children:** Not recommended. Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-Indications:** Combined use of 5-HT agonists. Hypersensitivity

operating machinery. History of mania. Caution in patients at risk of cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors: leave a seven day gap before starting MAO inhibitor treatment. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and tryptophan with caution. Routine monitoring of lithium levels need not be adjusted. **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. **Overdose:** Symptoms have included somnolence, coma, sinus tachycardia, occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request. Product licence holder: Lundbeck Ltd., Sunningdale House, Coldways Lake Business Park, Coldways, Milton Keynes, MK7 9LE. 'Cipramil' is a



THE BRITISH JOURNAL OF PSYCHIATRY

FEBRUARY 1997 VOL. 170

PROPERTY OF
ST. BARNABAS HOSPITAL
183rd ST. & 3rd AVE
BRONX, N. Y. 10457

EDITOR Greg Wilkinson LIVERPOOL

SENIOR ASSOCIATE EDITOR

Alan Kerr
NEWCASTLE UPON TYNE

ASSOCIATE EDITORS

Sidney Crown
LONDON

Julian Leff
LONDON

Sir Martin Roth
CAMBRIDGE

Sir Michael Rutter
LONDON

Peter Tyrer
LONDON

EDITORIAL ADVISERS

Herschel Prins
LEICESTER

Sir John Wood
SHEFFIELD

Kathleen Jones
YORK

ASSISTANT EDITORS

Mohammed Abou-Saleh
AL AIN

Louis Appleby
MANCHESTER

German Berrios
CAMBRIDGE

Alistair Burns
MANCHESTER

Patricia Casey
DUBLIN

John Cookson
LONDON

David Cottrell
LEEDS

Nigel Eastman
LONDON

Tom Fahy
LONDON

Anne Farmer
CARDIFF

Michael Farrell
LONDON

Nicol Ferrier
NEWCASTLE UPON TYNE

William Fraser
CARDIFF

Richard Harrington
MANCHESTER

Sheila Hollins
LONDON

Jeremy Holmes
BARNSTAPLE

Alexander Kellam
CARDIFF

Peter Kennedy
YORK

Michael King
LONDON

Alan Lee
NOTTINGHAM

Glyn Lewis
CARDIFF

Shôn Lewis
MANCHESTER

Robin McCreadie
DUMFRIES

Ian McKeith
NEWCASTLE UPON TYNE

Roy McClelland
BELFAST

Stuart Montgomery
LONDON

David Owens
LEEDS

Ian Pullen
EDINBURGH

Rosalind Ramsay
LONDON

Henry Rollin
LONDON

Jan Scott
NEWCASTLE UPON TYNE

Mike Shooter
CARDIFF

Andrew Sims
LEEDS

Jeanette Smith
BRISTOL

George Stein
LONDON

David Tait
PERTH

CORRESPONDING EDITORS

Sidney Bloch
AUSTRALIA

Patrice Boyer
FRANCE

J. M. Caldas de Almeida
PORTUGAL

Andrew Cheng
TAIWAN

Andrei Cristian
ROMANIA

E. L. Edelstein
ISRAEL

Václav Filip
CZECH REPUBLIC

Heinz Katschnig
AUSTRIA

Kenneth Kendler
USA

Toshi Kitamura
JAPAN

Arthur Kleinman
USA

F. Lieh Mak
HONG KONG

Jair Mari
BRAZIL

Harold Merskey
CANADA

Paul Mullen
AUSTRALIA

Ahmed Okasha
EGYPT

Volodymyr Poltavetz
UKRAINE

Michele Tansella
ITALY

Toma Tomov
BULGARIA

John Tsiantis
GREECE

J. L. Vázquez-Barquero
SPAIN

Richard Warner
USA

STATISTICAL ADVISER

Pak Sham
LONDON

STAFF

PUBLICATIONS MANAGER

Dave Jago

SCIENTIFIC EDITOR

Lesley Bennun

ASSISTANT SCIENTIFIC EDITORS

Dinah Alam

Andrew Morris

EDITORIAL ASSISTANTS

Zofia Ashmore

Julia Burnside

Sarah Fergie

MARKETING ASSISTANT

Dominic Bentham

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The BJP publishes original work in all fields of psychiatry. All communications, including manuscripts for publication should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG.

Full instructions to authors are given at the beginning of the January and July issues, and on the Web Site below.

Information about the College's publications is available on the World Wide Web at <http://www.demon.co.uk/rcpsych>.

Subscriptions

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1997 (12 issues post free) are as follows:

	INSTITUTIONS	INDIVIDUALS
Europe (& UK)	£165	£145
US	\$320	\$236
Elsewhere	£196	£155

Full airmail is £36/
US\$64 extra.

Single copies of the
journal are £14, \$25
(post free).

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

Payment should be made out to the British Journal of Psychiatry.

Back issues

Back issues published before 1996 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

Advertising

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (tel. 0181 642 0162; fax 0181 643 2275).

US Mailing Information

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$320. Second class postage paid at Rathway, NJ. Postmaster send address corrections to the British Journal of Psychiatry, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

™The paper used in this publication meets the minimum requirements of the American National Standard for Information Sciences - Permanence of Paper for Printed Library Materials, ANSI Z3948-1984.

Typeset by Dobbie Typesetting Ltd, Tavistock.

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

Past Editors

Eliot Slater	1961-72	John L. Crammer	1978-83
Edward H. Hare	1973-77	Hugh L. Freeman	1984-93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963.

©1997 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.

CONSULTANT PSYCHIATRIST

Eastern England

Enjoy a better quality of life in England's finest stone town which lies only twenty minutes' drive from the Consultant Psychiatrists' base hospital within this secure and successful £44 million turnover Trust, dedicated to providing accessible, high quality and effective healthcare services for its community of 400,000 people.

To strengthen the clinical leadership of its community-orientated mental health services, the Trust now seeks to appoint two high calibre Consultant Adult General Psychiatrists, one with a special interest in Drug Misuse and the other to take responsibility for the Court Diversion Scheme.

Serving the population of an attractive, prosperous, modern City, that tastefully combines the old with the new and is the headquarters location for many national and international businesses, the new District General Hospital, which opened in 1988 on a greenfield site, houses the Acute Psychiatry beds. The Trust enjoys excellent junior medical support, including several Senior Registrar posts in Adult Mental Health and related specialities.

These well-rewarded, prestigious appointments afford an

Top Level Salary + Benefits

opportunity to live in a most prosperous, attractive and accessible area of eastern England, served by excellent schools and charming towns and villages, with elegant and affordable executive residences both period and modern, and a wide range of leisure and sporting activities, yet less than sixty minutes from Central London with its unrivalled cultural, recreational and shopping facilities.

Male or female candidates should submit, in confidence, a comprehensive CV quoting reference number ZI/296 by 12th February 1997 to: ZIEGLER INTERNATIONAL, Consultants in Executive Search, The Jeffreys Building, Cowley Road, Cambridge CB4 4WS.


Tel: 01223 425030,

Fax: 01223 421863.

Assignment Briefing specifications available upon request.

Arrangements for site visits to be made through:

Janet Courtenay-Wilson/
Laurence Irvine, Director/s,
Ziegler International.



The Royal College of Psychiatrists' Journal of Continuing Professional Development



Advances in Psychiatric Treatment

Editor: Andrew Sims, *Director of Continuing Professional Development*

Subscription rate for **Volume 3, 1997**

(8 issues starting January 1996):

Europe, including UK £70.00

USA US\$110.00 Elsewhere £70.00

Full airmail £6/\$10 extra

APT with CPD registration £85.00

To enter your subscription or to obtain a sample copy of APT, contact: Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1M 0ZA, UK. Tel: +44(0)171 290 2927/8; Fax: +44(0)171 290 2929

College members wishing to receive APT and register for CPD should contact the Registration Department, Tel: +44(0)171 235 2351

Contents of the January 1997 issue

Development of new antidepressants. *E Palazidou*

Prevention of relapse and recurrence of depression: newer versus older antidepressants. *G Edwards*

Lessons to be learnt from meta-analysis of newer versus older antidepressants. *I Anderson*

Toxicity of newer versus older antidepressants. *J Henry*

The management of bulimia nervosa and other binge eating problems. *C Fairburn*

Fit to be interviewed by the police? *K Rix*

What a general practitioner can expect from a consultant psychiatrist. *A Wright*

The psychiatry of HIV. *J Catalan*

Somatoform and dissociative disorders: assessment and treatment. *C Bass, D Gill*

PSYCHIATRY IN PROGRESS

PROGRAMMES FOR ADVANCED
AND POSTGRADUATE TRAINING



For more than 10 years now, hospital Zon & Schild, one of the major psychiatric hospitals in the Netherlands, is organizing masterclasses in psychiatry and psychotherapy. In our programme 1997 - 1998 we present a course on

Personality Disorders

a series of two-day workshops on the etiology, development and treatment of personality disorders.

March	20 th + 21 th 1997	Michael Stone	<i>Personality: the concept, the models, the biology</i>
April	17 th + 18 th 1997	John Clarkin	<i>Research: the problems, the practice, the outcome Contract management</i>
August	28 th + 29 th 1997	Lawrence Rockland	<i>Supportive psychotherapy</i>
September	25 th + 26 th 1997	Otto Kernberg	<i>Expressive psychotherapy</i>
October	30 th + 31 th 1997	Salman Akhtar	<i>Integrated psychodynamic psychotherapy</i>
December	11 th + 12 th 1997	Arthur Freeman	<i>Cognitive psychotherapy</i>
March	5 th + 6 th 1998	Lorna Smith Benjamin	<i>Interpersonal diagnosis and treatment</i>
May	7 th + 8 th 1998	Glen Gabbard	<i>Pharmacotherapy, Pitfalls in psychotherapy</i>
June	1998	Marsha Linehan*	<i>Dialectical behavioral therapy</i>

Subscription is possible for each workshop separately or for the whole course. The price of each workshop is DFL 595,-- (approximately £ 195,--). The reduced price for the whole series is DFL 4760,-- (approximately £ 1560,--), including the book "Borderline Personality Disorder" by J. Paris. There is a 10% extra reduction for institutions that subscribe to six courses or more.

All workshops will be held at Psychiatric Center Zon & Schild, Amersfoort, the Netherlands.

Information : J. B. van Luyn, tel.: (+31) 33 4 609 503

Subscription : G. Pels - v.d. Heuvel, tel.: (+31) 33 4 609 852

* Or one of the senior trainers of Dialectical Behavioral Therapy. Exact dates have yet to be fixed.

ZON & SCHILD
psychiatrisch centrum

MAR 31 1997
PROPERTY OF
ST. BARNABAS HOSPITAL
183rd ST. & 3rd AVE.
BRONX, N. Y. 10450

An advance in the treatment of depression



DIRECTLY ACTS ON BOTH
SEROTONIN AND NORADRENALINE¹



HIGH RESPONSE RATES^{2,3}



REDUCES AGITATION⁴ AND IMPROVES
SLEEP PATTERNS⁵ AFTER 1 WEEK



LOW POTENTIAL FOR DRUG
INTERACTIONS^{**6-9}

** HEALTHY VOLUNTEER STUDIES

EFEXOR^{*}

VENLAFAXINE 37.5mg b.d.

SEROTONIN NORADRENALINE REUPTAKE INHIBITOR

PRESCRIBING INFORMATION: PRESENTATION: Tablets containing 37.5mg, 50mg or 75mg venlafaxine (as hydrochloride). USE: Treatment of depressive illness. DOSAGE: Usually 75mg/day (37.5mg bd) with food, increasing to 150mg/day (75mg bd) if necessary. In more severely depressed patients, 150mg/day (75mg bd) increasing every 2 or 3 days in up to 75mg/day increments to a maximum of 375mg/day, then reducing to usual dose consistent with patient response. Discontinue gradually. Elderly: use normal adult dose. Children: contraindicated. Doses should be reduced by 50% for moderate renal or moderate hepatic impairment. CONTRA-INDICATIONS: Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. PRECAUTIONS: Use with caution in patients with myocardial infarction, unstable heart disease, renal or hepatic impairment, or a history of epilepsy (discontinue in event of seizure). Patients should not drive or operate machinery if their ability to do so is impaired. Possibility of postural hypotension (especially in the elderly). Women of child-bearing potential should use contraception.

Prescribe smallest quantity of tablets according to good patient management. Monitor blood pressure with doses > 200mg/day. Advise patients to notify their doctor should an allergy develop or if they become or intend to become pregnant. Use with caution in patients taking other CNS-active drugs or in the elderly or hepatically-impaired patients taking cimetidine. Patients with a history of drug abuse should be monitored carefully. Not recommended in severe renal or severe hepatic impairment. INTERACTIONS: MAOIs: do not use EfeXOR in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping EfeXOR before starting a MAOI. SIDE-EFFECTS: Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, asthenia, sweating, nervousness, anorexia, dyspepsia, abdominal pain, anxiety, impotence, abnormality of accommodation, vasodilation, vomiting, tremor, paraesthesia, abnormal ejaculation/orgasm, chills, hypertension, palpitation, weight gain, agitation, decreased libido, rise in blood pressure, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol, hyponatraemia.

BASIC NHS PRICE: 37.5mg tablet (PL 0011/0199) – Calendar pack of 56 tablets: £23.97, 50mg tablet (PL 0011/0200) – Blister pack of 42 tablets: £23.97, 75mg tablet (PL 0011/0201) – Calendar pack of 56 tablets: £39.97. LEGAL CATEGORY: POM. Further information is available upon request. PRODUCT LICENCE HOLDER: Wyeth Laboratories (John Wyeth & Brother Limited), Taplow, Maidenhead, Berkshire, SL6 0PH. Space photography provided courtesy of National Aeronautics and Space Administration (NASA). References: 1. Muth EA *et al.* *Biochem Pharmacol* 1986; 35(24): 4493-4497. (EX00007). 2. Dierick M *et al.* *Prog Neuropsychopharmacol Biol Psychiat* 1996; 20: 57-71. 3. Clerc GE *et al.* *Int Clin Psychopharmacol* 1994; 9(3): 139-143. (EX00101). 4. Entsuah R *et al.* *Human Psychopharmacol* 1995; 10: 195-200. 5. Data on file, 635. 6. Troy SM *et al.* *J Clin Pharmacol* 1995; 35: 410-419. 7. Data on file, 20276. 8. Parker V *et al.* *J Clin Pharmacol* 1991; 3(9): 867 (Abstract 110). (EX00023). 9. Troy S *et al.* *Clin Neuropharm* 1992; 15(Suppl 1 pt.B): 324B. (EX00067). Date of preparation: September 1996. Code: Z776040/0996. *trade marks



Goodnight depression



THE
FIRST
ANTIDEPRESSANT
LICENSED FOR
PANIC
DISORDER†

Good morning world

Because most patients with depression suffer from insomnia and disturbed sleep,¹ an antidepressant should tackle this problem early on.

'Seroxat' has a difference, now well documented in major trials. It has the ability to match tricyclic efficacy in improving sleep by night, without the likelihood of sedation by day.^{2,3}

With 'Seroxat', you can give your patients much needed sleep as early as week one.⁴ You can lift both depression⁵ and anxiety² and reduce rather than increase agitation.⁶

It's a real difference for people needing the strength to face reality again, and a real reason to prescribe this SSRI, which is now also indicated for Panic Disorder and Obsessive Compulsive Disorder.

SEROXAT
PAROXETINE

30 mg paroxetine as the hydrochloride. 30 (OP) 20 mg tablets, £20.77; 30 (OP) 30 mg tablets, £31.16. **Indications:** Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. **Dosage:** *Adults: Depression:* 20 mg a day. Review response within two to three weeks and if necessary increase dose in 10 mg increments to a maximum of 50 mg according to response. *Obsessive compulsive disorder:* 40 mg a day. Patients should be given 20 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 60 mg a day. *Panic disorder:* 40 mg a day. Patients should be given 10 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 50 mg a day. Give orally once a day in the morning with food. The tablets should not be chewed. Continue treatment for a sufficient period, which may be several months for depression or longer for OCD and panic disorder. As with many psychoactive medications abrupt discontinuation should be avoided - see **Adverse reactions**. *Elderly:* Dosing should commence at the adult starting dose and may be increased in weekly 10 mg increments up to a maximum of 40 mg a day according to response. *Children:* Not recommended. *Severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment:* 20 mg a day. Restrict incremental dosage if required to lower end of range. **Contra-indication:** Hypersensitivity to paroxetine. **Precautions:** History of mania. Cardiac conditions: caution. Caution in patients with epilepsy; stop treatment if seizures develop. Driving and operating machinery. **Drug interactions:** Do not use with or within two weeks after MAO inhibitors; leave a two-week gap before starting MAO inhibitor treatment. Possibility of interaction with tryptophan. Great caution with warfarin and other oral anticoagulants. Use lower doses if given with drug metabolising enzyme inhibitors; adjust dosage if necessary with drug metabolising enzyme inducers. Alcohol is not advised. Use lithium with caution and monitor lithium levels. Increased adverse effects with phenytoin; similar possibility with other anticonvulsants. **Pregnancy and lactation:** Use only if potential benefit outweighs possible risk. **Adverse reactions:** In controlled trials most commonly nausea, somnolence, sweating, tremor, asthenia, dry mouth, insomnia, sexual dysfunction (including impotence and ejaculation disorders), dizziness, constipation and decreased appetite. Also spontaneous reports of dizziness, vomiting, diarrhoea, restlessness, hallucinations, hypomania, rash including urticaria with pruritus or angioedema, and symptoms suggestive of postural hypotension. Extrapyramidal reactions reported infrequently; usually reversible abnormalities of liver function tests and hyponatraemia described rarely. Symptoms including dizziness, sensory disturbance, anxiety, sleep disturbances, agitation, tremor, nausea, sweating and confusion have been reported following abrupt discontinuation of 'Seroxat'. It is recommended that when antidepressant treatment is no longer required, gradual discontinuation by dose-tapering or alternate day dosing be considered. **Overdosage:** Margin of safety from available data is wide. Symptoms include nausea, vomiting, tremor, dilated pupils, dry mouth, irritability, sweating and somnolence. No specific antidote. General treatment as for overdose with any antidepressant. Early use of activated charcoal suggested. **Legal category:** POM. 1.7.96. † In the UK. **References:** 1. Fleming J. *Prog Neuro-Psychopharmacol, Biol Psychiatr* 1989;13:419-29. 2. Hutchinson D et al. *Br J Clin Res* 1991;2:43-57. 3. Hindmarch I. *Int Clin Psychopharmacol* 1992;6(Suppl 4):65-7. 4. Dunbar GC et al. *Acta Psychiatr Scand* 1993;87:302-5. 5. Medicines Resource Centre. *Int Pharm J* 1992;6:6-9. 6. Dunbar GC, Fuel DL. *Int Clin Psychopharmacol* 1992;6(Suppl 4):81-9. 7. Dorman T. *Int Clin Psychopharmacol* 1992;6(Suppl 4):53.

SB SmithKline Beecham
Pharmaceuticals

SmithKline Beecham Pharmaceuticals,
Welwyn Garden City, Hertfordshire
AL7 1EY.

'Seroxat' is a registered trade mark.
© 1996 SmithKline Beecham Pharmaceuticals
STEAD/6/551JP

CLOZARIL ABBREVIATED PRESCRIBING INFORMATION. The use of CLOZARIL is restricted to patients registered with the CLOZARIL Patient Monitoring Service. Indication: Treatment-resistant schizophrenia (patients non-responsive to, or intolerant of, conventional neuroleptics). Presentations 25 mg and 100 mg clozapine tablets. Dosage and Administration Initiation of CLOZARIL treatment must be in hospital in-patients and is restricted to those patients with a normal white blood cell count and differential count. Initially, 12.5 mg once or twice on first day, followed by one or two 25 mg tablets on second day. Increase slowly, initially by daily increments of 25 to 50 mg, followed by increments of 50 to 100 mg to reach a therapeutic dose within the range of 200 to 450 mg daily. The total daily dose should be divided and a larger portion of the dose may be given at night. Once control is achieved a maintenance dose of 150 to 300 mg daily may suffice. At daily doses not exceeding 200mg, a single administration in the evening may be appropriate. Exceptionally, doses up to 900 mg daily may be used. Patients with a history of epilepsy should be closely monitored during CLOZARIL therapy since dose-related convulsions have been reported. Therefore, patients with a history of seizures, as well as those suffering from cardiovascular, renal or hepatic disorders, together with the elderly need lower doses (12.5 mg given once on the first day) and more gradual titration. Contra-Indications Hypersensitivity to clozapine. History of drug-induced neutropenia/agranulocytosis, myeloproliferative disorders, uncontrolled epilepsy, alcoholic and toxic psychoses, drug intoxication, comatose conditions, circulatory collapse and/or CNS depression of any cause and severe hepatic, renal or cardiac failure. Warning CLOZARIL can cause agranulocytosis. A fatality rate of up to 1 in 300 has been estimated when CLOZARIL was used prior to recognition of this risk. Since that time strict haematological monitoring of patients has been demonstrated to be effective in markedly reducing the risk of fatality. Because of the risk associated with CLOZARIL therapy its use is therefore limited to treatment-resistant schizophrenic patients: 1. who have normal leucocyte findings (white blood cell count and differential blood count), and 2. in whom regular leucocyte counts can be performed weekly during the first 18 weeks and at least every two weeks thereafter for the first year of therapy. After one years treatment monitoring may be changed to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue as long as treatment continues. Patients must be under specialist supervision and CLOZARIL supply is restricted to hospital and community pharmacies registered with the CLOZARIL Patient Monitoring Service. Prescribing physicians must register themselves, their patients and a nominated pharmacist with the CLOZARIL Patient Monitoring Service. This service provides for the required leucocyte counts as well as a drug supply audit so that CLOZARIL treatment is promptly withdrawn from any patient who develops abnormal leucocyte findings. Each time CLOZARIL is prescribed, patients should be reminded to contact the treating physician immediately if any kind of infection begins to develop. Particular attention should be paid to flu-like complaints or other symptoms which might suggest infection, such as fever or sore throat. Precautions CLOZARIL can cause agranulocytosis. Perform pre-treatment white blood cell count and differential count to ensure only patients with normal findings receive CLOZARIL. Monitor white blood cell count weekly for the first 18 weeks and at least two-weekly for the first year of therapy. After one years treatment, monitoring may be changed to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue as long as treatment continues. If the white blood count falls below $3.0 \times 10^9/l$ and/or the absolute neutrophil count drops below $1.5 \times 10^9/l$, withdraw CLOZARIL immediately and monitor the patient closely, paying particular attention to symptoms suggestive of infection. Re-evaluate any patient developing an infection, or with a routine white blood count between 3.0 and $3.5 \times 10^9/l$ and/or a neutrophil count between 1.5 and $2.0 \times 10^9/l$, with a view to discontinuing CLOZARIL. Any further fall in white blood/neutrophil count below $1.0 \times 10^9/l$ and/or $0.5 \times 10^9/l$ respectively, after drug withdrawal requires immediate specialised care. Where protective isolation and administration of GM-CSF or G-CSF may be indicated. Colony stimulating factor therapy should be discontinued when the neutrophil count returns above $1.0 \times 10^9/l$. CLOZARIL lowers the seizure threshold. Orthostatic hypotension can occur therefore close medical supervision is required during initial dose titration.

Monitor hepatic function in liver disease. Use with care in prostatic enlargement, narrow-angle glaucoma and paralytic ileus. Patients affected by the sedative action of CLOZARIL should not drive or operate machinery. CLOZARIL should be administered with caution to patients who participate in activities requiring complete mental alertness. Patients with fever should be carefully evaluated to rule out the possibility of an underlying infection or the development of agranulocytosis. Do not give CLOZARIL with other drugs with a substantial potential to depress bone marrow function. CLOZARIL may enhance the effects of alcohol, MAO inhibitors, CNS depressants and drugs with anticholinergic, hypotensive or respiratory depressant effects. Caution is advised when CLOZARIL therapy is initiated in patients who are receiving (or have recently received) a benzodiazepine or any other psychotropic drug as these patients may have an increased risk of circulatory collapse, which, on rare occasions, can be profound and may lead to cardiac and/or respiratory arrest. Caution is advised with concomitant administration of therapeutic agents which are highly bound to plasma proteins. Clozapine binds to and is partially metabolised by the isoenzyme cytochrome P450 2D6. Caution is advised with drugs which possess affinity for the same isoenzyme. Concomitant cimetidine and high dose CLOZARIL was associated with increased plasma clozapine levels and the occurrence of adverse effects. Discontinuation of concomitant carbamazepine resulted in increased clozapine levels. Phenytoin decreases clozapine levels resulting in reduced effectiveness of CLOZARIL. No clinically relevant interactions noted with antidepressants, phenothiazines and type Ic antiarrhythmics observed, to date. Isolated reports of fluvoxamine increasing clozapine plasma levels by 5-10 fold. Concomitant use of lithium or other CNS-active agents may increase the risk of neuroleptic malignant syndrome. The hypertensive effect of adrenaline and its derivatives may be reversed. Do not use in pregnant or nursing women. Use adequate contraceptive measures in women of child bearing potential. Side-Effects Neutropenia leading to agranulocytosis (See Warning and Precautions). Rare reports of leucocytosis including eosinophilia. Isolated cases of leukaemia and thrombocytopenia have been reported but there is no evidence to suggest a causal relationship with the drug. Most commonly fatigue, drowsiness, sedation. Dizziness or headache may also occur. CLOZARIL lowers the seizure threshold and may cause EEG changes and delirium. Myoclonic jerks or convulsions may be precipitated in individuals who have epileptogenic potential but no previous history of epilepsy. Rarely it may cause confusion, restlessness, agitation and delirium. Extrapyrmidal symptoms are limited mainly to tremor, akathisia and rigidity. Neuroleptic malignant syndrome has been reported. Transient autonomic effects eg dry mouth, disturbances of accommodation and disturbances in sweating and temperature regulation. Hypersalivation. Tachycardia and postural hypotension, with or without syncope, and less commonly hypertension may occur. In rare cases profound circulatory collapse has occurred. ECG changes, arrhythmias, pericarditis and myocarditis (with or without eosinophilia) have been reported, some of which have been fatal. Isolated cases of respiratory depression or arrest, with or without circulatory collapse. GI disturbances, increases in hepatic enzymes. In rare cases, cholestasis has been reported and very rarely ileus may occur. Rarely aspiration may occur in patients presenting with dysphagia or as a consequence of acute overdosage. Both urinary incontinence and retention and priapism have been reported. Benign hyperthermia may occur and isolated reports of skin reactions have been received. Rarely, hyperglycaemia has been reported. Rarely increases in CPK values have occurred. With prolonged treatment considerable weight gain has been observed. Sudden unexplained deaths have been reported in patients receiving CLOZARIL. Package Quantities and Price Community pharmacies only. 28 x 25mg tablets: £12.52 (Basic NHS) 28 x 100mg tablets: £50.05 (Basic NHS). Hospital pharmacies only. 84 x 25 mg tablets: £37.54 (Basic NHS). 84 x 100 mg tablets: £150.15 (Basic NHS). Supply of CLOZARIL is restricted to hospital and community pharmacies registered with the CLOZARIL Patient Monitoring Service. Product Licence Numbers 25 mg tablets: PL 0101/0228. 100 mg tablets: PL 0101/0229. Legal Category POM. CLOZARIL is a registered Trade Mark. Date of preparation January 1996. Full prescribing information, including Product Data Sheet is available from SANDOZ PHARMACEUTICALS. Frimley Business Park, Frimley, Camberley, Surrey, GU16 5SG.

After two neuroleptics had failed
Clozaril got to work...



...so did Steve

How long should you wait?

CLOZARIL[®]
clozapine

Proven efficacy in treatment-resistant schizophrenia

**WE WON'T
PROMISE
THE WORLD**



**BUT ZYPREXA MAY
FIND A PLACE**

ABBREVIATED PRESCRIBING INFORMATION: **Presentation:** Coated tablets containing 5mg, 7.5mg or 10mg of olanzapine. The tablets also contain lactose. **Uses:** Schizophrenia, both as initial therapy and for maintenance of response. **Further Information:** In studies of patients with schizophrenia and associated depressive symptoms, mood score improved significantly more with olanzapine than with haloperidol. Olanzapine was associated with significantly

greater improvements in both negative and positive schizophrenic symptoms than placebo or comparator in most studies. **Dosage and Administration:** 10mg/day orally, as a single dose without regard to meals. Dosage may subsequently be adjusted within the range of 5-20mg daily. An increase to a dose greater than the routine therapeutic dose of 10mg/day is recommended only after clinical assessment. **Children:** Not recommended under 18 years of age. **The elderly:** A lower starting dose (5mg/day) is not routinely indicated but should be considered when clinical factors warrant. **Hepatic and/or renal impairment:** A lower starting dose (5mg) may be considered. When more than one factor is present which might result in slower metabolism (female gender, elderly age, non-smoking status), consideration should be given to decreasing the starting dose. Dose escalation should be conservative in such patients. **Contraindications:** Known hypersensitivity to any ingredient of the product. Known risk for narrow-angle glaucoma. **Warnings and Special**

Precautions: Caution in patients with prostatic hypertrophy, or paralytic ileus and related conditions. Caution in patients with elevated ALT and/or AST, signs and symptoms of hepatic impairment pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. As with other neuroleptic drugs, caution in patients with low leucocyte and/or neutrophil counts for any reason, a history of drug-induced bone marrow depression/toxicity, bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hyper eosinophilic conditions or with myeloproliferative disease. Thirty-two patients with clozapine-related neutropenia or agranulocytosis histories received olanzapine without decreases in baseline neutrophil counts. Although, in clinical trials, there were no reported cases of NMS in patients receiving olanzapine, if such an event occurs, or if there is unexplained high fever, all antipsychotic drugs, including olanzapine, must be discontinued.





schizophrenia treatments can't promise to put patients' lives back the way they were. But the right choice of medication may help them find a place in their community.

Zyprexa demonstrated improvement in the negative as well as the positive symptoms of schizophrenia (in four out of five controlled trials in patients presenting with both positive and negative symptoms).¹⁻³

With a simple once-daily dosage and no requirement for routine blood or ECG monitoring,⁴ Zyprexa may offer a step towards community re-integration.

Antipsychotic Efficacy for First-line Use

ZYPREXA
Olanzapine



Making Community Re-integration the Goal

Caution in patients who have a history of seizures or have conditions associated with seizures. If signs or symptoms of tardive dyskinesia appear a dose reduction or drug discontinuation should be considered. Caution when taken in combination with other centrally acting drugs and alcohol. Olanzapine may antagonise the effects of direct and indirect dopamine agonists. Postural hypotension was infrequently observed in the elderly. However, blood pressure should be measured periodically in patients over 65 years, as with other antipsychotics. As with other antipsychotics, caution when prescribed with drugs known to increase QTc interval, especially in the elderly. In clinical trials, olanzapine was not associated with a persistent increase in absolute QT intervals. **Interactions:** Metabolism may be induced by concomitant smoking of carbamazepine therapy. **Pregnancy and Lactation:** Olanzapine had no teratogenic effects in animals. Because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Olanzapine was excreted in the milk of treated rats but it is not known if it is excreted in human milk. Patients should be advised not to breast feed an infant if they are taking olanzapine. **Driving, etc:** Because olanzapine may cause somnolence, patients should be cautioned about operating hazardous machinery, including motor vehicles. **Undesirable Effects:** The only frequent (>10%) undesirable effects associated with the use of olanzapine in clinical trials were somnolence and weight gain. Occasional undesirable effects included dizziness, increased appetite, peripheral oedema, orthostatic hypotension, and mild, transient anticholinergic effects, including constipation and dry mouth. Transient, asymptomatic elevations of hepatic transaminases, ALT, AST have been seen occasionally. Olanzapine-treated patients had a lower incidence of Parkinsonism, akathisia and dystonia in trials compared with titrated doses of haloperidol. Photosensitivity reaction or high creatinine clearance levels were reported rarely. Discontinuation of olanzapine was sometimes

elevated, but associated clinical manifestations were rare. Asymptomatic haematological variations were occasionally seen in trials. *For further information see summary of product characteristics. Legal Category: POM. Marketing Authorisation Numbers: EU/1/96/022/004 EU/1/96/022/006 EU/1/96/022/009 EU/1/96/022/010. Basic NHS Cost: £52.73 per pack of 28 x 5mg tablets. £105.47 per pack of 28 x 10mg tablets. £158.20 per pack of 56 x 7.5mg tablets. £210.93 per pack of 56 x 10mg tablets. Date of Preparation: August 1996. Full Prescribing Information is Available From: Lilly Industries Limited, Dextra Court, Chapel Hill, Basingstoke, Hampshire RG21 5SY. Telephone: Basingstoke (01256) 315000. 'ZYPREXA' is a Lilly trademark. References: 1. Data on file, Lilly Industries. 2. Data on file, Lilly Industries. 3. Zyprexa Summary of Product Characteristics, Section 5.1: Pharmacodynamic Properties. 4. Zyprexa Summary of Product Characteristics.*

Published online by Cambridge University Press

<https://doi.org/10.1192/S000712260046495>

New Zimovane™ LS.

Half the strength for added flexibility in the elderly.




Zimovane™
zopiclone 7.5mg

NEW 
Zimovane™ **LS**
Low Strength
zopiclone 3.75mg

A non-benzodiazepine that's just right for the elderly.

Presentation: Zimovane™: white film coated tablets containing 7.5mg zopiclone. Zimovane™ LS: blue film coated tablets containing 3.75mg zopiclone. The tablets also contain lactose, cellulose and sodium. **Pharmacology:** Zopiclone is a non-benzodiazepine hypnotic, a member of the cyclopyrrolone group of compounds which is structurally unrelated to existing hypnotics and tranquillisers. **Indications:** Short term treatment of insomnia which is debilitating or causing severe distress for the patient. A course of treatment should not be longer than 4 weeks. **Dosage and Administration:** Adults: One 7.5mg tablet shortly before retiring. Elderly and renally impaired: A lower dose of 3.75mg zopiclone is recommended initially. The dosage subsequently may be increased to 7.5mg if clinically necessary. Hepatic insufficiency: A lower dose of 3.75mg is recommended. **Contra-indications:** Myasthenia gravis, respiratory failure, severe sleep apnoea syndrome, severe hepatic insufficiency, hypersensitivity to zopiclone. As with all hypnotics zopiclone should not be used in children. **Precautions:** Zopiclone is not a treatment for depression. Hepatic or renal insufficiency: A lower dose of 3.75mg zopiclone is recommended. **Pregnancy and lactation:** Use of zopiclone is not recommended. **Risk of dependence:**

who abuse drugs or alcohol, or who have marked personality disorders. **Withdrawal:** Withdrawal effects are unlikely although all patients should be monitored. **Interactions:** Alcohol, CNS depressant, tricyclic antidepressants. **Adverse Effects:** Most frequently, mild bitter or metallic after-taste, mild gastrointestinal disturbances. Occasionally drowsiness on waking, dizziness, light-headedness and incoordination. Although residual effects are rare, patients should not drive or operate machinery until it is established that performance is unimpaired. Psychological and behavioural disturbances and allergic manifestations such as urticaria or rash have been reported. Rebound insomnia on discontinuation of treatment and anterograde amnesia should not be excluded. **Legal Category:** POM. **Pharmaceutical Precautions:** Protect from light. Store in a dry place below 30°C. **Presentation and Basic NHS Cost:** Zimovane™ tablets: PL12/0259; 28 x 7.5mg tablets Basic NHS cost: £4.48. Zimovane™ LS: PL12/0260; 28 x 3.75mg tablets Basic NHS cost: £3.08. **Date of Preparation:** July 1996. Further information is available on request from Rhône-Poulenc Rorer, RPR House, St Leonards Road, Eastbourne, East Sussex BN21 3YG. ZIM 9896

™denotes Registered Trademark

 RHÔNE-POULENC RORER

Half-Inderal LA
propranolol

Zoladex
goserelin 3.6 mg

Tenormin LS
atenolol 50 mg

Arimidex
anastrozole

Casodex
bicalutamide

Tomudex
raltitrexed

And you thought
you'd never heard
of Zeneca

Vivalan
viloxazine

Avloclor
chloroquine
phosphate

Mysoline
primidone

Zestril
lisinopril

Zoladex LA
goserelin 10.8 mg

Meronem
meropenem

Nolvadex
tamoxifen

Diprivan 1%
propofol

All names quoted thus:
'Tenormin' are trademarks.

Indications include:

'Half-Inderal LA' - Anxiety
'Zoladex LA' - Prostate cancer
suitable for hormonal manipulation
'Zoladex' - Endometriosis

'Tenormin LS' - Hypertension
'Arimidex' - Advanced breast
cancer, after tamoxifen, or other
antioestrogens, in post-menopausal
women
'Tomudex' - Palliative treatment of
advanced colorectal cancer, where
5-FU and folinic acid based

regimens are either not tolerated
or inappropriate
'Casodex' - Advanced prostate
cancer, with an LHRH analogue
or surgical castration
'Vivalan' - Symptoms of
depressive illness
'Avloclor' - Treatment of malaria

'Mysoline' - Grand mal epilepsy
'Meronem' - Septicaemia (organisms
susceptible to 'Meronem')
'Nolvadex' - Breast cancer
'Zestril' - Hypertension/adjunctive
therapy in CHF
'Diprivan 1%' - Maintenance of
(general) anaesthesia



Granted To ICI Pharmaceuticals

Further information is available from ZENECA Pharma,
King's Court, Water Lane, Wilmslow, Cheshire SK9 5AZ.

2563

Legal Category POM

96/6084 (cccc) Issued October 1996



ZENECA



Recent Council Reports

CR50 'Wish you were here'? Ethical considerations in the admission of patients
to substandard psychiatric units, £2.50

CR51 The responsibilities of consultant psychiatrists, £5.00

CR52 Sexual abuse and harassment in psychiatric settings, £5.00

CR53 Assessment and clinical management of risk of harm to other people, £3.00

CR54 Chronic fatigue syndrome, £10.00

Available from the
Publications Department,
Royal College of Psychiatrists,
17 Belgrave Square,
London SW1X 8PG
Tel. +44(0)171 235 2351,
extension 146

COLLEGE SEMINARS SERIES

College Seminars is a series of textbooks covering the breadth of psychiatry. As well as helping junior doctors during their training years, College Seminars will make a contribution to the continuing medical education of established clinicians.

Seminars in Liaison Psychiatry

Edited by Elspeth Guthrie & Francis Creed

Moving from the psychiatric in-patient and out-patient settings to the general medical wards can be disorientating and difficult. The clinical problems are different. In this text, recognised experts in liaison psychiatry guide the trainee through the various difficulties of interviewing, assessing and formulating the psychological problems found in patients in general medical units.

£15.00, 312pp, 1996, ISBN 0 902241 95 8

Seminars in Clinical Psychopharmacology

Edited by David J. King

Linking relevant basic neuropharmacology to clinical practice, this book is an excellent introduction to an ever-expanding and fascinating subject. It aims to bridge the gap between the theoretical basis for the mode of action of psychotropic drugs and guidance on the clinical standing of the drugs widely used in medical practice.

£20.00, 544pp, 1995, ISBN 0 902241 73 7

Seminars in Alcohol and Drug Misuse

Edited by Jonathan Chick & Roch Cantwell

A clear review of the aetiology, epidemiology, treatment and prevention of dependence on and misuse of alcohol and illicit and prescribed drugs is presented. With a balance of theory, recent research and practical clinical guidelines, the book covers specific and common problems in mental health as well as in general medicine.

£13.50, 246pp, 1994, ISBN 0 902241 70 2

Other books in the series

Seminars in Basic Neurosciences

£15.00, 336pp, 1993, ISBN 0902241 61 3

Seminars in Child and Adolescent Psychiatry

£15.00, 298pp, 1993, ISBN 0902241 55 9

Seminars in Practical Forensic Psychiatry

Edited by Derek Chiswick & Rosemary Cope

A concise account of the specialty from a strongly practical perspective. This book systematically describes the relationship between psychiatric disorders and offending, with detailed discussion of the criminal justice system, court proceedings, mental health legislation, dangerousness, prison psychiatry, and civil issues. It is up-to-date, with references to the Reed report, the Clunis Inquiry, supervision registers and recent legislation. Career guidance and a chapter on ethical issues are included.

£17.50, 359pp, 1995, ISBN 0 902241 78 8

Seminars in Psychiatric Genetics

By P. McGuffin, M.J. Owen, M.C. O'Donovan, A. Thapar & I.I. Gottesman

Comprehensive coverage of what is known of the genetics of psychiatric disorders, and an introduction to the relevant quantitative and molecular genetic methods.

£10.00, 240pp, 1994, ISBN 902241 65 6

Seminars in Psychology and the Social Sciences

Edited by Digby Tantam & Max Birchwood

The theories considered in this book are likely to dominate the research and service agenda over the next decade. Ethnicity as a determinant of health care, connectionist models of mental functioning, and the effects of sex and gender on mental health are some of the theories covered here.

£17.50, 358pp, 1994, ISBN 0 902241 62 1

Titles in preparation

Adult Psychiatric Disorders Due for publication Spring 1997

Learning Disabilities Spring 1997

Psychosexual Disorders Spring 1997

Gaskell is the imprint of the Royal College of Psychiatrists. The books in this series and other College publications are available from good bookshops and from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.



Credit card orders can taken over the telephone (+44(0)171 235 2351, extension 146).


The latest information on College publications is available on the INTERNET at:

<http://www.demon.co.uk/rcpsych/>

Now we've turned our thoughts to psychiatry.

Zeneca are currently undertaking a comprehensive programme of events aimed at supporting those involved in caring for the seriously mentally ill.

- A series of annual regional workshops - Management Issues in Schizophrenia.
 - The Zeneca/BAP Annual Poster Award.
- The Zeneca/UKPPG Travel Award.
 - RCP/NSF Schizophrenia Information Leaflets.
- Sponsorship of UK CPNA conferences.
- First annual CPNA/Zeneca conference to be held in England.
 - A practical handbook about schizophrenia for families.*
- A pocketbook guide to schizophrenia.
 - Research fora, to investigate controversies in community care, advances in pharmaceutical therapies and managing treatment-resistant patients.



ZENECA

THINKING AHEAD IN PSYCHIATRY

For more information on these events, please call Zeneca Pharma on 0800 200 123.

* Available from January 1997

Eastern Health Board/Beaumont Hospital/
Royal College of Surgeons in Ireland, Dublin, Ireland

The Eastern Health Board's psychiatric services in Dublin North City and County (Catchment Area 8) are being integrated with Beaumont Hospital, where an acute psychiatric admission unit is being commissioned, and with the Royal College of Surgeons in Ireland in relation to under-graduate and post-graduate medical training.

In line with this development the following posts are being filled:

Post (1) CLINICAL DIRECTOR/CONSULTANT PSYCHIATRIST

Post (2) PROFESSOR OF PSYCHIATRY/CONSULTANT PSYCHIATRIST

Post (3) CONSULTANT PSYCHIATRIST (LIAISON)

These posts are joint appointments. **Posts (1) and (2)** are on a geographical whole-time basis (11 sessions per week) and **Post (3)** is on an existing whole-time basis (11 sessions per week).

The scheduled commitment for the three posts is as follows:

Post 1 8 sessions per week to the Eastern Health Board.
3 sessions per week to Beaumont Hospital.

Post 2 5 sessions per week to the Royal College of Surgeons in Ireland.
3 sessions per week to the Eastern Health Board.
3 sessions per week to Beaumont Hospital.

Post 3 8 sessions per week to Beaumont Hospital.
3 sessions per week to Eastern Health Board.

The following professional qualifications and experience will apply to these appointments:

(a) the possession of the M.D. degree* in psychiatry of a recognised university or the M.R.C.P.I. in psychiatry or Membership of the Royal College of Psychiatrists or the Diploma in Psychological Medicine awarded before February 1972, or a professional qualification at least equivalent to one of these.

(*other than a primary degree)

(b) at least seven years' satisfactory experience (after becoming entitled to full registration) in the practice of the medical profession, including not less than five years' satisfactory experience in psychiatry; and, in relation to **Post No. 3** at least seven years' satisfactory experience (after becoming entitled to full registration) in the practice of the medical profession, including not less than five years' satisfactory experience in psychiatry of which at least one year was in liaison psychiatry.

Applicants for **Posts (1) and (3)** should forward their Curriculum Vitae (15 copies per post) together with the names and addresses of four referees (of whom at least two should refer to recent appointments) to the Recruitment and Training Section, Personnel Department, Beaumont Hospital, Beaumont, Dublin 9, Ireland. (Tel: 00 353 1 8377755) from whom further particulars may be obtained on request.

Applicants for **Post (2)** should forward their Curriculum Vitae (15 copies) together with the names and addresses of four referees (of whom at least two should refer to recent appointments) to the Human Resources Manager, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland. (Tel: 00 353 1 4022339. Fax: 00 353 1 4022456) from whom further particulars may be obtained on request. Closing date for receipt of all applications is 14th March, 1997.

The Eastern Health Board, Beaumont Hospital and R.C.S.I. are equal opportunity employers.

ABBREVIATED PRESCRIBING INFORMATION

Please refer to summary of product characteristics before prescribing

Risperdal (risperidone)

USES The treatment of acute and chronic schizophrenia, and other psychotic conditions, in which positive and/or negative symptoms are prominent. Risperdal also alleviates affective symptoms associated with schizophrenia. **DOSAGE** Where medically appropriate, gradual discontinuation of previous antipsychotic treatment while Risperdal therapy is initiated is recommended. Where medically appropriate, when switching patients from depot antipsychotics, consider initiating Risperdal therapy in place of the next scheduled injection. The need for continuing existing antiparkinsonian medication should be re-evaluated periodically. **Adults:** Risperdal may be given once or twice daily. All patients, whether acute or chronic, should start with 2mg/day. This should be increased to 4mg/day on the second day and 6mg/day on the third day. From then on the dosage can be maintained unchanged, or further individualised if needed. The usual optimal dosage is 4 to 8 mg/day. Doses above 10mg/day may increase the risk of extrapyramidal symptoms and should only be used if the benefit is considered to outweigh the risk. Doses above 16mg/day should not be used. **Elderly, renal and liver disease:** A starting dose of 0.5mg b.d. is recommended. This can be individually adjusted with 0.5mg b.d. increments to 1 to 2mg b.d. Use with caution in these patients. Not recommended in children aged less than 15 years. **CONTRAINDICATIONS, WARNINGS ETC.** Contraindications: Known hypersensitivity to Risperdal. **Precautions:** Orthostatic hypotension can occur (alpha-blocking effect). Use with caution in patients with known cardiovascular disease. Consider dose reduction if hypotension occurs. For further sedation, give an additional drug (such as a benzodiazepine) rather than increasing the dose of Risperdal. Drugs with dopamine antagonistic properties have been associated with tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotic drugs should be considered. Caution should be exercised when treating patients with Parkinson's disease or epilepsy. Patients should be advised of the potential for weight gain. Risperdal may interfere with activities requiring mental alertness. Patients should be advised not to drive or operate machinery until their individual susceptibility is known. **Pregnancy and lactation:** Use during pregnancy only if the benefits outweigh the risks. Women receiving Risperdal should not breast feed. **Interactions:** Use with caution in combination with other centrally acting drugs. Risperdal may antagonise the effect of levodopa and other dopamine agonists. On initiation of carbamazepine or other hepatic enzyme-inducing drugs, the dosage of Risperdal should be re-evaluated and increased if necessary. On discontinuation of such drugs, the dosage of Risperdal should be re-evaluated and decreased if necessary. **Side effects:** Risperdal is generally well tolerated and in many instances it has been difficult to differentiate adverse events from symptoms of the underlying disease. Common adverse events include: insomnia, agitation, anxiety, headache. Less common adverse events include: somnolence, fatigue, dizziness, impaired concentration, constipation, dyspepsia, nausea/vomiting, abdominal pain, blurred vision, priapism, erectile dysfunction, ejaculatory dysfunction, orgasmic dysfunction, urinary incontinence, rhinitis, rash and other allergic reactions. The incidence and severity of extrapyramidal symptoms are significantly less than with haloperidol. However, the following may occur: tremor, rigidity, hypersalivation, bradykinesia, akathisia, acute dystonia. If acute, these symptoms are usually mild and reversible upon dose reduction and/or administration of antiparkinsonian medication. Rare cases of Neuroleptic Malignant Syndrome have been reported. In such an event, all antipsychotic drugs should be discontinued. Occasionally, orthostatic dizziness, orthostatic hypotension and reflex tachycardia have been observed, particularly with higher initial doses. An increase in plasma prolactin concentration can occur which may be associated with galactorrhoea, gynaecomastia and disturbances of the menstrual cycle. Oedema and increased hepatic enzyme levels have been observed. A mild fall in neutrophil and/or thrombocyte count has been reported. Rare cases of water intoxication with hyponatraemia, tardive dyskinesia, body temperature dysregulation and seizures have been reported. **Overdosage:** Reported signs and symptoms include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. A prolonged QT interval was reported in a patient with concomitant hypokalaemia who had ingested 360 mg. Establish and maintain a clear airway, and ensure adequate oxygenation and ventilation. Gastric lavage and activated charcoal plus a laxative should be considered. Commence cardiovascular monitoring immediately, including continuous electrocardiographic monitoring to detect possible arrhythmias. There is no specific antidote, so institute appropriate supportive measures. Treat hypotension and circulatory collapse with appropriate measures. In case of severe extrapyramidal symptoms, give anticholinergic medication. Continue close medical supervision and monitoring until the patient recovers. **PHARMACEUTICAL PRECAUTIONS** Tablets: Store between 15°C and 30°C, in a dry place and protected from light. Liquid: Store between 15°C and 30°C and protect from freezing. **LEGAL CATEGORY POM. PRESENTATIONS, PACK SIZES, PRODUCT LICENCE NUMBERS & BASIC NHS COSTS** White, oblong tablets containing 1mg risperidone in packs of 20. PL 0242/0186 £13.45. Pale orange, oblong tablets containing 2mg risperidone in packs of 60. PL 0242/0187 £79.56. Yellow, oblong tablets containing 3mg risperidone in packs of 60. PL 0242/0188 £117.00. Green, oblong tablets containing 4mg risperidone in packs of 60. PL 0242/0189 £154.44. Starter packs containing 6 Risperdal 1mg tablets are also available £4.15. Clear, colourless solution containing 1mg risperidone per ml in bottles containing 100ml. PL 0242/0199 £65.00. **FURTHER INFORMATION IS AVAILABLE FROM THE PRODUCT LICENCE HOLDER:** Janssen-Cilag Ltd, Saunderton, High Wycombe, Buckinghamshire, HP14 4HJ. References: Ereshefsky L, Lancombe S. Can J Psychiatry 1993; 38(suppl 3): S80-S88. Saller CF et al. J Pharmacol Exp Ther 1990; 253: 1162-1170. Data on file, Janssen-Cilag Ltd. Peuskens J. et al. BJ Psych 1995; 166: 712-726. Marder SR. & Meibach RC. Am J Psych 1994; 151: 825-835. Emsley RA. et al. NR465 [N111877] Klieser E. et al. J Clin Psychopharmacol 1995; 15 (Suppl 1):45S-51S. Lindstrom E. et al. Clin Ther 1995; 17 (No.3). (Reprint)

©

TM denotes Trademark

Date of preparation: March 1996

0098119



JANSSEN-CILAG Ltd



Patient with schizophrenia exercises *self* discipline by going wild



The SDA effect of Risperdal can mean a huge difference to the lives of patients with schizophrenia.

Because SDA is the action of Serotonin and Dopamine Antagonism in a single drug. In positive and negative symptoms. In first episode and acute presentations, and in chronic patients. Risperdal continues to provide this SDA effect to give high efficacy, with low levels of extrapyramidal side effects, to more and more patients.

Helping them keep out of hospitals while enhancing their appreciation of, and participation in, community and family life. It's not called the great outdoors for nothing.



Risperdal[™]
RISPERIDONE

A routine route out

THE 1996 PFIZER PRIZE IN NEUROCLINICAL & BIOLOGICAL PSYCHIATRY

WHO ARE PFIZER?

We are an internationally-respected, global healthcare company. We express our serious commitment to original Research and Development through our annual R&D allocation of on average £900 million. As the manufacturers of various products, we have a particular interest in CNS-related innovation.

THE PRIZE

A bursary of £3000 and publication of the winning submission in the *Journal of Human Psychopharmacology* will be awarded for original and excellent research conducted in the field of Neuroclinical and Biological Psychiatry.

THE JUDGES

Your entry will be judged by 10 key opinion leaders, chaired by Professor Brian Leonard, University College Galway, and Professor Ted Dinan of St. Bartholomew's Hospital London.

If you are conducting postgraduate research in this or related fields, entry forms can be obtained in January 1997 from your local Pfizer representative, or from: Jemima Maxwell, Pfizer Research Prize, 3rd Floor, Africa House, 64 Kingsway, London WC2B 6AH



HELPING YOU TO HELP YOUR PATIENTS

66864B Dec 96

NB MEDICAL EDUCATION

LONDON

MRCPsych PART 1

Intensive exam-oriented weekend courses

- Covering: Theory for *new syllabus*
Technique & tactics
Over 2000 relevant MCQs
Practice MCQ exams
- Dates: London: 1, 2 & 8, 9 March 1997
The Secretary
NB Medical Education
PO Box 767
Oxford
OX1 2YU
- Full details: 01865 514019
- HM 67 (27) approval for study leave

DIRECT MEDICAL APPOINTMENTS

LOCUM positions available NOW
Long or Short Term
Top Rates
All areas of the UK

Choice of Consultant Posts

Documentation/Visas arranged

Permanent and Substantive Positions

**CALL NOW FOR A
PROFESSIONAL SERVICE**

**Tel: +44 (0)1792 472525
Fax: +44 (0)1792 472535**

SHE'S CARED FOR 4 CHILDREN, 10 GRANDCHILDREN AND 2 HUSBANDS.

BUT SHE CAN'T COPE WITH DEPRESSION ALONE



Treats older patients with the respect they deserve

Molipaxin[®]
trazodone HCl

Many capsules, Molipaxin tablets, Molipaxin CR tablets 150mg, Molipaxin Liquid (50mg/5ml). Indications: Relief of symptoms in all types of depression including depression accompanied by anxiety. Symptoms likely to respond in the first week include depressed mood, insomnia, anxiety, somatic symptoms and hypochondriasis. Dosage and Administration: Starting dose of Molipaxin is 150mg daily taken in divided doses after food or as a single dose on retiring. This may be increased to 300mg/day the major portion of which is preferably taken on retiring. In hospitalised patients, dosage may be further increased to 600mg/day in divided doses. Dosage in the elderly and frail: Starting dose of 100mg/day in divided doses or as a single night-time dose. This may be increased, under supervision, according to efficacy and tolerance. Doses above 300mg/day are unlikely to be required. Cessation of Molipaxin should be gradual. Children: Not recommended. Contraindications: Known sensitivity to trazodone. Precautions: Avoid during first trimester of pregnancy and in nursing mothers. Warn against risks of handling machinery and driving. May enhance muscle relaxants, some antihypertensive agents, sedatives or antidepressants and alcohol, acute effects of clonidine may be reduced. Avoid concurrent therapy with MAOIs and do not give Molipaxin within 2 weeks of stopping MAOIs or give MAOIs within 1 week of stopping Molipaxin. Use with care in patients with epilepsy, severe hepatic, cardiac or renal disease. Patients receiving long-term therapy with any antidepressant should be kept under regular surveillance. Side effects: Molipaxin is a sedative antidepressant. Any dizziness or drowsiness usually disappears on continued dosage. Anticholinergic-like symptoms occur, but the incidence is similar to placebo. Blood dyscrasias, including agranulocytosis, thrombocytopenia and anaemia, have been reported on rare occasions. Adverse effects on hepatic function, including jaundice and hepatocellular damage, sometimes severe, have been rarely reported. Should such effects occur, Molipaxin should be discontinued immediately. As with other drugs with alpha-adrenergic activity, Molipaxin has very rarely been associated with priapism. This may be treated with an intracavernosal injection of alpha-adrenergic agents such as adrenaline or metaraminol. However, there are reports of trazodone-induced priapism which have on occasion required surgical intervention or led to permanent sexual dysfunction. Priapism should be dealt with as an urological emergency and Molipaxin therapy should be discontinued immediately. Other side effects include isolated cases of oedema and postural hypotension. Overdosage: No specific antidote is available. Give supportive and symptomatic treatment. Legal Category: POM. Presentations, product licence numbers and basic NHS prices: Molipaxin 50mg, 84 capsules; 0109/0045; £17.31. Molipaxin 100mg, 56 capsules; 0109/0046; £20.38. Molipaxin 150mg, 28 tablets; 0109/0133; £11.62. Molipaxin CR 150mg, 28 tablets; 0109/0214; £11.62. Molipaxin Liquid 50mg/5ml, 150ml bottle; 0109/0117; £7.74. Product Licence Holder: Roussel Laboratories Ltd, Broadwater Park, Denham, Uxbridge, Middlesex UB9 5HP. Distributor: Marion Merrell Ltd, Broadwater Park, Denham, Uxbridge, Middlesex UB9 5HP. Further product information is available from Hoechst Marion Roussel at the above address. Hoechst Marion Roussel is a member of the Hoechst Group. © Molipaxin is a registered trademark.

Date of issue: Dec 1996

Another seizure

Wasn't late getting up

Didn't let fish off hook

Adjunctive treatment for partial seizures

TOPAMAX Abbreviated Prescribing Information. Please read the data sheet before prescribing.

Presentation: Tablets each imprinted "TOP" on one side and strength on the other containing 25mg (white), 50mg (light yellow), 100mg (yellow), and 200mg (salmon) topiramate. **Uses:** Adjunctive therapy of partial seizures, with or without secondarily generalised seizures, in patients inadequately controlled on conventional first line antiepileptic drugs.

Dosage and Administration: *Adults and Elderly:* Oral administration. Usual dose: 200mg - 600mg/day in two divided doses. See data sheet for titration. Do not break tablets. It is not necessary to monitor topiramate plasma concentrations. Patients with

Contra-indications: Hypersensitivity to any component of the product. **Precautions and Warnings:** Withdraw all antiepileptic drugs gradually. Maintain adequate hydration to reduce risk of nephrolithiasis (especially increased in those with a predisposition). Drowsiness likely. TOPAMAX may be more sedating than other antiepileptic drugs therefore caution in patients driving or operating machinery, particularly until patients' experience with the drug is established. Do not use in pregnancy unless potential benefit outweighs risk to foetus. Women of child bearing potential should use adequate contraception. Do not use if breastfeeding. **Interactions:** *Other Antiepileptic Drugs:* No clinically significant effect except in some patients on phenytoin where phenytoin plasma concentrations may increase. Phenytoin level

ure-free day

Didn't fall in water

Didn't have a seizure



TOPAMAX[®]
topiramate

At the end of the day, it works.

with or without secondary generalisation

concentration. No clinically significant changes in plasma concentrations on sodium valproate addition or withdrawal. Digoxin: A decrease in serum digoxin occurs. Monitor serum digoxin on addition or withdrawal of TOPAMAX. Oral Contraceptives: Should contain not less than 50µg of oestrogen. Ask patients to report any change in bleeding patterns. Others: Avoid agents predisposing to nephrolithiasis. Side Effects: In 5% or more: ataxia, impaired concentration, confusion, dizziness, fatigue, paraesthesia, somnolence and abnormal thinking. May cause agitation and emotional lability (which may manifest as abnormal behaviour) and depression. Less commonly: anorexia, anorexia, aphasia, diplopia, nausea, nystagmus, speech disorder, taste perversion, abnormal vision and weight decrease. Increased risk of

treatment as appropriate. Haemodialysis is effective in removing topiramate. **Pharmaceutical Precautions:** Store in a dry place at or below 25°C. **Legal Category:** POM. **Package Quantities and Prices:** Bottles of 60 tablets. 25mg (PL0242/0301) = £22.02; 50mg (PL0242/0302) = £36.17; 100mg (PL0242/0303) = £64.80; 200mg (PL0242/0304) = £125.83. **Product Licence Holder:** JANSSEN-CILAG LIMITED, SAUNDERTON, HIGH WYCOMBE, BUCKINGHAMSHIRE HP14 4HJ Further information is available on request from the Marketing Authorisation Holder: Janssen-Cilag Limited, Saunderton, High Wycombe, Buckinghamshire HP14 4HJ. © Registered Trademark © Janssen-Cilag Limited 1996 Date of Preparation Aug 1996



Psychological Trauma - A Developmental Approach

Edited by Dora Black, Martin Newman, Jean Harris Hendriks and Gillian Mezey

This is the first UK textbook on psychological trauma and contains contributions by many of the country's leading authorities on responses to traumatic events. It is edited by four clinicians with extensive experience on this subject.

The book discusses normal and abnormal responses to stress, disasters, war and civil conflict, and interpersonal violence, diagnosis, interventions and treatments, and legal aspects.

There is reference throughout to the research findings, and discussion of future research needs. Each chapter contains a comprehensive bibliography for those who wish to read further.

Intended primarily for psychiatrists and other health and social services professionals, it will also prove an invaluable aid to solicitors and lawyers working in this field, as well as to those who plan responses to disasters and help organise services. It will also provide a useful introduction to trainees in the various mental health and legal disciplines interested in this subject. *Published December 1996, price £30.00, 424pp. ISBN 0 902241 98 2*

Available from bookshops and from the Publications Department, Royal College of Psychiatrists,
17 Belgrave Square, London SW1X 8PG. Tel. +44(0)171 235 2351, extension 146

GASKELL ACADEMIC SERIES

Speech and Language Disorders in Psychiatry


Edited by Andrew Sims

Descriptive psychopathology provides a different and refreshing approach to the understanding of mental illness. *Speech and Language Disorders in Psychiatry* starts from this standpoint and links research into speech and language disorder with clinical psychiatry. In particular, it provides a detailed and comprehensive account of current research into schizophrenic speech and language disorder. The authors of this collection of articles are leading authorities in psychiatry, neurology, psychology and communications. *£20.00, 206pp., Hardback, 1995, ISBN 0 902241 79 6*

Gaskell is the imprint of the Royal College of Psychiatrists. Gaskell books are available from good bookshops and from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146). The latest information on College publications is available on the INTERNET at: <http://www.demon.co.uk/rcpsych/>



New Brief Pulse ECT with *Computer-Assisted* Easy Seizure Monitoring



Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in U.S.A., Canada, and Mexico by:



SOMATICS, INC.
910 Sherwood Drive # 17
Lake Bluff IL 60044 U.S.A.

Fax: (847) 234-6763
Tel: (847) 234-6761

Selected Distributors

Distributed in the U.K. by: DANTEC Electronics, Ltd.
Garonor Way
Royal Portbury
Bristol BS20 9XE
TEL (44) 1275-375333
FAX (44) 1275-375336

Distributed in New Zealand by: WATSON VICTOR, Ltd.
4 Adelaide Rd.
Wellington, New Zealand
TEL (64) 4-385-7699
FAX (64) 4-384-4651

Distributed in India by: DIAGNO.SYS
New Delhi
TEL (91) 11-644-0546
FAX (91) 11-622-9229

Distributed in South Africa by: DELTA SURGICAL
Craighall
TEL (27) 11-792-6120
FAX (27) 11-792-6926

Distributed in Australia by: MEECO Holdings Pty. Ltd.
10 Seville St.
North Parramatta NSW 2151
Australia
TEL (61) 2630-7755
FAX (61) 2630-7365

Distributed in Scandinavia by: MEDICAL EQUIPMENT APS
Bygaden 51A
P.O. Box 23
DK-4040
Jyllinge, Denmark
TEL (45) 4-6788746
FAX (45) 4-6788748

Distributed in Pakistan by: IQBAL & CO.
Islamabad
TEL (92) 51-291078
FAX (92) 51-281623

Distributed in Israel by: BEPEX, LTD.
16, Galgalei Haplada St.
Herzliya 46722
TEL (972) 9-959586211
FAX (972) 9-9547244

WORLD MENTAL HEALTH CARE FROM GASKELL



Available from good bookshops and from the Publications Department, Royal College of Psychiatrists,
17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146)

Mental Disorders in China

English Version Editors:
John E. Cooper & Norman Sartorius

This is the first available account in English of the results of the 1982 Chinese Epidemiological Survey of Mental Disorder. It is the only nationwide Chinese study to involve modern methods of case assessment and is uniquely large and interesting, involving 51 982 persons. The use of the Present State Examination in the survey allows the symptomatic basis of diagnoses, such as neurasthenia, to be examined. The results indicate that the prevalence of schizophrenia is similar to that found recently in other countries, but that the prevalence of other mental disorders may be lower.
£15.00, 128pp., 1996, ISBN 0 902241 931

Mental Health Care in China

State Policies, Professional Services and Family Responsibilities

by Veronica Pearson

This book traces the development of psychiatric services in China. Historical, policy and legal frameworks are constructed to provide a context in which psychiatric services may be better understood. The experience of both staff and patients in one particular hospital is examined in detail. The book raises questions about the similarities in the experience of psychiatric illness across significantly different cultures.
£12.50, 218pp., 1995, ISBN 0 902241 74 5

**BPP
MEDICAL
EDUCATION**

Intensive weekend courses
BPP training centre, London

**MRCPsychiatry Parts I & II
Written and Clinical skills courses**

Part I Written 15-16 March 1997
Part II Written 15-16 March 1997
Part II Clinical 3-4 May 1997

BPP Courses are
Stimulating, entertaining and successful.

Telephone or Fax 0181-959-7562
33 Flower Lane, Mill Hill, London NW7

POST TRAUMATIC STRESS AND DISSOCIATION

**3RD ANNUAL ISSD (UK) CONFERENCE
9-11 APRIL**

UNIVERSITY COLLEGE CHESTER

Speakers include:

Prof. Steven Braude
Philosopher & Author, "First Person Plural"
University of Maryland

Dr. Mark Mayal
Consultant Child & Adolescent Psychiatrist, Suffolk

Dr. John Davis
Senior Lecturer & Clinical Psychologist, University of Warwick

Registration forms/ Programmes available from
ISSD (UK)
20 Walpole Street
Chester, CH1 4HG
01244 390121 (tel) 01244 390374 (fax)

**SPECIAL DISCOUNTS FOR BOOKINGS
MADE BEFORE 1 MARCH 1997**

WORLD MENTAL HEALTH CARE FROM GASKELL



Available from good bookshops and from the Publications Department, Royal College of Psychiatrists,
17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146)

Psychiatry for the Developing World

Edited by Digby Tantam, Louis Appleby and
Alice Duncan

Written by psychiatrists from the developing world, this is an up-to-date and comprehensive multi-author volume on psychiatry as it can be practised in developing countries today. All aspects of psychiatry are covered, both administrative and practical, and advice is given on planning, training and conducting research. Recommendations on treatment of common psychiatric disorders are also provided, following ICD-10 classification standards.

£25.00, 376pp., 1996, ISBN 1 902241 86 9

Mental Health Services in the Global Village

Edited by Louis Appleby & Ricardo Araya

Throughout the world, cultural and economic circumstances are a powerful influence on mental illness - its frequency, recognition and treatment. *Mental Health Services in the Global Village* is a review of the care of the mentally ill around the world, its ideals, inequalities, progress and mistakes. The contributors' opinions on how mental health services will develop as the end of the century approaches reflect the prospects for the World Health Organization's goal of "Health for All".

£10.00, 221pp., 1991, ISBN 0 902241 40 0